2025-09-15 - Analysis Report
Okay, here's an analysis of TransMedics Group Inc. (TMDX) based on the provided data, presented in a structured format with key figures first, followed by more detailed analysis.

**Executive Summary**

TMDX has significantly outperformed the S&P 500 (VOO) historically, but recent price action suggests some caution.  Analyst sentiment is generally positive, with a "Buy" consensus.  Recent earnings have exceeded expectations, and revenue/profitability metrics are strong. However, recent price movement suggests a pull back, and the valuation is not cheap.

**1. Relative Performance vs. S&P 500 (VOO)**

*   **Cumulative Return:**
    *   TMDX: 213.24%
    *   VOO: 76.05%
*   **Relative Deviation:**
    *   Current Deviation: 135.1
    *   Relative Deviation (Percentile): 55.9%

**Analysis:** TMDX has substantially outperformed VOO. The current deviation of 135.1 indicates a significant lead in cumulative returns. However, a relative deviation percentile of 55.9% suggests that the outperformance, while substantial, is not at its absolute peak historically relative to the data provided.

*TransMedics Group Inc. (TMDX) is a medical technology company focused on developing and delivering innovative organ care system platforms for end-stage organ failure patients.*

**Alpha/Beta Analysis:**

| Year       | CAGR     | MDD   | Alpha  | Beta | Cap(B) |
|------------|----------|-------|--------|------|--------|
| 2019-2021  | -4.0%    | 63.4% | -52.0% | 0.0  | 0.7    |
| 2020-2022  | 140.0%   | 68.3% | 138.0% | 0.1  | 2.1    |
| 2021-2023  | 95.0%    | 69.4% | 77.0%  | 0.2  | 2.7    |
| 2022-2024  | 147.0%   | 82.8% | 121.0% | 0.2  | 2.1    |
| 2023-2025  | 94.0%    | 82.8% | 38.0%  | 0.5  | 3.9    |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):**  Highly variable, ranging from negative to very high positive values.
*   **MDD (Maximum Drawdown):** Consistently high, indicating significant volatility.
*   **Alpha:** Generally positive, showing outperformance relative to the market on a risk-adjusted basis. The Alpha values have declined more recently.
*   **Beta:** Low Beta suggests a low Correlation with the market, this can be misleading as the beta seems unstable over time.
*   **Market Cap (B):** Shows significant growth in market capitalization over time.

**2. Recent Stock Price Movement**

*   **Current Price:** 114.565
*   **Last Market Close:**
    *   Price: 114.565
    *   Previous Close: 116.99
    *   Change: -2.07
*   **Moving Averages:**
    *   5-day: 110.641
    *   20-day: 114.635
    *   60-day: 118.4746

**Analysis:** The price is slightly below the 20-day moving average and significantly below the 60-day moving average, indicating potential short-term weakness and a possible downtrend. The price decreased by 2.07 from the previous close, signaling a recent drop.

**3. Market Risk Indicators and Expected Return**

*   **MRI (Market Risk Indicator):** 0.3233 (Low Risk)
*   **RSI (Relative Strength Index):** 42.87 (Neutral)
*   **PPO (Percentage Price Oscillator):** 0.1516
*   **Hybrid Signal:** cash_6%_Buy 90% of cash
*   **Delta_Previous_Relative_Divergence:** 2.1 (+)
*   **Expected Return:** 75.7%

**Analysis:**

*   The low MRI suggests that current market conditions present a lower level of systematic risk.
*   RSI is below 50, indicating neutral to slightly bearish momentum.
*   The positive delta in relative divergence suggests some short-term upward momentum.
*   A high expected return (75.7%) indicates potential for significant long-term outperformance if you invest for the long term.
*   The last price change of -2.07 indicates recent price pullback, potentially creating a buying opportunity.

**4. Recent News & Significant Events**

*   **Positive Sentiment from Analysts:** Multiple articles highlight Wall Street's bullishness and TMDX as a top growth stock.
*   **Insider Buying:** News of insider increasing their holding suggests confidence in the company's future prospects.
*   **Mixed Analyst Actions:** Stifel initiated coverage with a "Neutral" rating and a $115 price target, which is relatively close to the current price.
*   **Post-Earnings Dip:** One article points out a slight dip after the last earnings report, potentially indicating some market correction or profit-taking.

**Analysis:** The news is predominantly positive, with analyst recommendations and insider buying suggesting strong potential. The mixed Stifel rating may indicate a more cautious or valuation-sensitive outlook.

**4-2. Analyst Opinions**

*   **Consensus:** Buy
*   **Mean Rating:** 1.78 (~Buy)
*   **Number of Opinions:** 8
*   **Target Price:**
    *   Average: 138.88
    *   High: 170.00
    *   Low: 114.00

**Analysis:** The consensus is strongly bullish, with a "Buy" rating from a significant number of analysts. The average target price is significantly above the current price, suggesting substantial upside potential. However, the low target is equal to the current price, so some analysts are more cautious.

**5. Recent Earnings Analysis**

| Date       | EPS  | Expected EPS |
|------------|------|--------------|
| 2025-07-30 | 0.92 | 0.48         |
| 2025-05-08 | 0.7  | 0.29         |
| 2025-02-27 | 0.19 | 0.22         |
| 2024-10-28 | 0.12 | 0.29         |
| 2024-07-31 | 0.35 | 0.21         |

**Analysis:** TMDX has consistently beaten EPS estimates in recent quarters. This indicates strong performance and positive earnings momentum. Note, however, that estimates for Q4 2024 was higher than the reported EPS, suggesting some analyst disappointment on revenues, margins or costs.

**6. Financial Information**

*   **Revenue and Profitability:**

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2025-06-30 | $0.16B   | 61.38%        |
| 2025-03-31 | $0.14B   | 61.47%        |
| 2024-12-31 | $0.12B   | 59.21%        |
| 2024-09-30 | $0.11B   | 55.94%        |
| 2024-06-30 | $0.11B   | 60.59%        |

*   **Capital and Profitability:**

| Quarter    | Equity   | ROE    |
|------------|----------|--------|
| 2025-06-30 | $0.32B   | 10.97% |
| 2025-03-31 | $0.27B   | 9.64%  |
| 2024-12-31 | $0.23B   | 3.00%  |
| 2024-09-30 | $0.21B   | 2.01%  |
| 2024-06-30 | $0.19B   | 6.42%  |

**Analysis:**

*   **Revenue:** Shows consistent growth over the past five quarters.
*   **Profit Margin:** Consistently high, indicating strong operational efficiency.
*   **Equity:** Increasing steadily, reflecting positive earnings and retained profits.
*   **ROE (Return on Equity):** Improving over time, indicating that the company is generating more profit from shareholders' investments.

**7. Overall Assessment**

TMDX demonstrates a high-growth profile with significant historical outperformance compared to the S&P 500. Strong revenue growth, high profit margins, and consistent EPS beats suggest a healthy business trajectory. Positive analyst sentiment and insider buying further reinforce this view.

However, recent price action indicates potential short-term weakness, and the high valuation implied by past performance and analyst targets may make the stock vulnerable to correction. Investors should weigh the potential for future growth against the risk of valuation pullback. Consider a long-term perspective with staggered investments. The Hybrid signal recommends a "cash_6%_Buy 90% of cash" strategy, indicating a cautious yet opportunistic approach.
